• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    11/14/24 5:51:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TERN alert in real time by email
    SC 13G/A 1 tm2428137d17_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

    Terns Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    880881107

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨  Rule 13d-1(b)
       
    x  Rule 13d-1(c)
       
    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 880881107 Page 2 of 13

     

    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,516,8892

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,516,8892

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,516,8892

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    1Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of immediately exercisable warrants (“Warrants”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
    3This percentage is calculated based upon the sum of (i) 70,371,911 shares of the Issuer’s Common Stock outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2024; and (ii) 106,831 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 880881107 Page 3 of 13

     

    1.

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,516,8892

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,516,8892

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,516,8892

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
    3This percentage is calculated based upon the sum of (i) 70,371,911 shares of the Issuer’s Common Stock outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2024; and (ii) 106,831 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 880881107 Page 4 of 13

     

    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,516,8892

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,516,8892

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,516,8892

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    1Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
    3This percentage is calculated based upon the sum of (i) 70,371,911 shares of the Issuer’s Common Stock outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2024; and (ii) 106,831 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 880881107 Page 5 of 13

     

    1.

    Name of reporting persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,516,8892

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,516,8892

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,516,8892

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
    3This percentage is calculated based upon the sum of (i) 70,371,911 shares of the Issuer’s Common Stock outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2024; and (ii) 106,831 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. 880881107 Page 6 of 13

     

    1.

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,516,8892

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,516,8892

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,516,8892

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
    3This percentage is calculated based upon the sum of (i) 70,371,911 shares of the Issuer’s Common Stock outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2024; and (ii) 106,831 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 880881107 Page 7 of 13

     

    1.

    Name of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,516,8892

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,516,8892

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,516,8892

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    1Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
    3This percentage is calculated based upon the sum of (i) 70,371,911 shares of the Issuer’s Common Stock outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2024; and (ii) 106,831 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 880881107 Page 8 of 13

     

    1.

    Name of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,516,8892

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,516,8892

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,516,8892

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    1Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.
    2Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
    3This percentage is calculated based upon the sum of (i) 70,371,911 shares of the Issuer’s Common Stock outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2024; and (ii) 106,831 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 880881107 Page 9 of 13

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Terns Pharmaceuticals, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Terns Pharmaceuticals, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    1065 East Hillsdale Blvd., Suite 100

    Foster City, California 94404

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share

     

      (e) CUSIP Number

     

    880881107

     

     

     

     

    CUSIP No. 880881107 Page 10 of 13

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   3,516,889 
    VHCP Co-Investment Holdings III, LLC   3,516,889 
    Venrock Healthcare Capital Partners EG, L.P.   3,516,889 
    VHCP Management III, LLC   3,516,889 
    VHCP Management EG, LLC   3,516,889 
    Nimish Shah   3,516,889 
    Bong Koh   3,516,889 

     

      (b) Percent of Class as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.     
    VHCP Co-Investment Holdings III, LLC     
    Venrock Healthcare Capital Partners EG, L.P.     
    VHCP Management III, LLC     
    VHCP Management EG, LLC     
    Nimish Shah     
    Bong Koh     

     

      (c) Number of shares as to which the person has, as of September 30, 2024:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners III, L.P.     
    VHCP Co-Investment Holdings III, LLC     
    Venrock Healthcare Capital Partners EG, L.P.     
    VHCP Management III, LLC     
    VHCP Management EG, LLC     
    Nimish Shah     
    Bong Koh     

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners III, L.P.   3,516,889 
    VHCP Co-Investment Holdings III, LLC   3,516,889 
    Venrock Healthcare Capital Partners EG, L.P.   3,516,889 
    VHCP Management III, LLC   3,516,889 
    VHCP Management EG, LLC   3,516,889 
    Nimish Shah   3,516,889 
    Bong Koh   3,516,889 

     

     

     

     

    CUSIP No. 880881107 Page 11 of 13

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners III, L.P.     
    VHCP Co-Investment Holdings III, LLC     
    Venrock Healthcare Capital Partners EG, L.P.     
    VHCP Management III, LLC     
    VHCP Management EG, LLC     
    Nimish Shah     
    Bong Koh     

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners III, L.P.   3,516,889 
    VHCP Co-Investment Holdings III, LLC   3,516,889 
    Venrock Healthcare Capital Partners EG, L.P.   3,516,889 
    VHCP Management III, LLC   3,516,889 
    VHCP Management EG, LLC   3,516,889 
    Nimish Shah   3,516,889 
    Bong Koh   3,516,889 

     

    1Consists of (i) 685,355 shares and 29,067 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 68,560 shares and 2,908 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,656,143 shares and 74,856 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

      

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 880881107 Page 12 of 13

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.
       
    By: VHCP Management III, LLC  
    Its: General Partner  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  
       
    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  
       
    VHCP Management III, LLC  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  
       
    Venrock Healthcare Capital Partners EG, L.P.  
       
    By: VHCP Management EG, LLC  
    Its: General Partner  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  
       
    VHCP Management EG, LLC  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  
       
    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  
       
    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

     

     

    CUSIP No. 880881107 Page 13 of 13

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on August 29, 2022)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on August 29, 2022)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on August 29, 2022)

     

     

    Get the next $TERN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TERN

    DatePrice TargetRatingAnalyst
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    11/3/2025Mkt Perform → Outperform
    William Blair
    10/15/2025$20.00Buy
    Truist
    9/17/2025$15.00Overweight
    Barclays
    9/4/2025Neutral
    H.C. Wainwright
    2/28/2025Mkt Perform
    William Blair
    10/31/2024$82.00Outperform
    Oppenheimer
    6/22/2023$16.00Buy
    Mizuho
    More analyst ratings

    $TERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gengos Andrew bought $39,283 worth of shares (10,000 units at $3.93), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/30/25 5:38:10 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Burroughs Amy L. bought $90,230 worth of shares (23,314 units at $3.87), increasing direct ownership by 98% to 47,083 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/25/25 6:08:58 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Gengos Andrew bought $57,082 worth of shares (15,000 units at $3.81) (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/16/25 6:05:21 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are $747.5 million. All of the securities were off

    12/11/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Pricing of Upsized $650 Million Public Offering

    FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an add

    12/9/25 11:30:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Proposed Public Offering

    FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares and pre-funded warrants to be sold in th

    12/9/25 6:12:55 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Quigley Jill M. exercised 24,520 shares at a strike of $9.24 and sold $441,360 worth of shares (24,520 units at $18.00) (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    11/5/25 6:17:46 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kuriakose Emil sold $7,407 worth of shares (944 units at $7.85), decreasing direct ownership by 2% to 51,520 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    10/2/25 7:24:36 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kuriakose Emil sold $3,640 worth of shares (853 units at $4.27), decreasing direct ownership by 2% to 52,464 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    7/3/25 2:55:49 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Terns Pharmaceuticals upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Terns Pharmaceuticals from Neutral to Buy and set a new price target of $20.00

    11/4/25 8:12:25 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by William Blair

    William Blair upgraded Terns Pharmaceuticals from Mkt Perform to Outperform

    11/3/25 10:27:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Terns Pharmaceuticals with a new price target

    Truist initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    10/15/25 8:33:02 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    SEC Filings

    View All

    SEC Form 8-K filed by Terns Pharmaceuticals Inc.

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/11/25 7:45:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Terns Pharmaceuticals Inc.

    424B5 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/11/25 7:44:01 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Terns Pharmaceuticals Inc.

    424B5 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/9/25 7:46:21 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Leadership Updates

    Live Leadership Updates

    View All

    Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

    FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor

    2/24/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

    FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa

    2/20/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

    FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide

    11/18/24 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Financials

    Live finance-specific insights

    View All

    Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

    64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today a

    12/8/25 2:45:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We're thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1

    11/10/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

    Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hema

    11/3/25 9:05:00 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 5:51:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care